Page last updated: 2024-09-05

sorafenib and cp 547632

sorafenib has been researched along with cp 547632 in 6 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(cp 547632)
Trials
(cp 547632)
Recent Studies (post-2010) (cp 547632)
6,5207305,25119113

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)cp 547632 (IC50)
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0093
Glycogen synthase kinase-3 betaHomo sapiens (human)0.0715
Angiopoietin-1 receptorHomo sapiens (human)0.319
Discoidin domain-containing receptor 2Homo sapiens (human)0.237

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Engel, J; Grütter, C; Nguyen, HD; Phan, T; Rauh, D; Richters, A; Simard, JR1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

6 other study(ies) available for sorafenib and cp 547632

ArticleYear
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Biochemistry, 2007, Aug-21, Volume: 46, Issue:33

    Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin

2007
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
    ACS chemical biology, 2012, Jul-20, Volume: 7, Issue:7

    Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Identification of type II and III DDR2 inhibitors.
    Journal of medicinal chemistry, 2014, May-22, Volume: 57, Issue:10

    Topics: Discoidin Domain Receptors; Drug Design; Fluorescence; High-Throughput Screening Assays; Ligands; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structure-Activity Relationship

2014
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017